Soliqua is a revolutionary brand in diabetes medication, created and marketed by Sanofi. This medication has been skillfully designed for adults with type 2 diabetes to improve their blood sugar control. Soliqua combines two potent active ingredients, insulin glargine and lixisenatide, which are essential in controlling high blood sugar levels. Insulin glargine is a long-acting insulin lowerer, while lixisenatide is a glucagon-like peptide-1 receptor agonist. These scientific interventions are great to stimulate the body’s insulin production and inhibit glucose production, which collectively balances the blood sugar level.
What makes Soliqua a paradigm in diabetes medication is its functionality. It is normally used when diet and exercise are not enough to control blood sugar and when long-acting insulin or lixisenatide alone do not provide enough blood sugar control. However, it should not be used to treat type 1 diabetes or diabetic ketoacidosis.
Soliqua promises comfort and ease of use with its injectable pen, perfect for self-administration. This medication is available through Canadian Insulin, an online pharmacy that provides a range of breakthrough medications to Canadian and international customers. Canadian Insulin remarkably extends its reach by offering an accessible way to receive necessary medications such as Soliqua conveniently and cost-effectively.